CellCept is a medicine prescribed to prevent organ rejection in people who have a kidney, liver, or heart transplant. It comes in the form of a capsule, a tablet, a liquid suspension, or an intravenous injection. It works by making the immune system less active, so it does not attack the new organ. Common side effects include pain, swelling, and high blood pressure.
What Is CellCept?CellCept® (mycophenolate mofetil) is a prescription medication approved to prevent organ rejection in people who have received a heart, kidney, or liver transplant. It is used in combination with cyclosporine (Gengraf®, Neoral®, Sandimmune®) and a corticosteroid medication (such as prednisone). CellCept comes in the form of a tablet, a capsule, a liquid suspension, and an intravenous (IV) injection.
Mycophenolate, the active ingredient in CellCept, is available as mycophenolate sodium in Myfortic®. CellCept and Myfortic are not interchangeable medications, as they contain different forms of mycophenolate and they affect the body in different ways.
Who Makes This Medication?CellCept is made by F. Hoffmann-La Roche, Ltd., and distributed by Genentech USA, Inc.
How Does CellCept Work?CellCept works by blocking the action of an enzyme in the body known as inosine monophosphate dehydrogenase (IMPDH). This enzyme is needed for T- and B-lymphocytes (cells that are part of the immune system) to multiply.
Transplant rejection occurs when the immune system, which is responsible for fighting infections, identifies the transplanted organ as a foreign material and tries to get rid of it. By preventing the production of more T- and B-lymphocytes, CellCept makes the immune system less active, which can help prevent transplant rejection.